Add the specialty areas of your choice to tailor excemed.org to your professional interests.
Save & Create free account
No thanks, just apply selection
I already have an account. Login

User login

We offer our registered users tailored information, free online courses and exclusive content.

Can't find your password?
Reset it here.

Grand Rounds metastatic colorectal cancer 2017

Grand Rounds metastatic colorectal cancer 2017
  • Oncology
  • Metastatic colorectal cancer
Regional workshop by Excemed
Thursday, Dec 21 - Friday, Dec 22 2017
Dubai, United Arab Emirates
Registration status
Closed

Target audiences

This programme is intended for oncologists and practicing clinicians who have an interest in understanding colorectal cancer biology and building individual competencies in the management of the disease.

Files

Introduction

Access learning resources by clicking the Outcomes tab or scroll down to the Scientific Programme.

Overview

The development of new drugs and the interdisciplinary management of the disease have resulted in a meaningful increase in survival for patients with metastatic colorectal cancer. As the number of therapeutic options increases, insights into the biology of the disease and biomarker-driven therapeutic strategies are expected to improve patients survival and rationalize therapeutic approaches. Recent data reveals that right- and left-sided primary colorectal cancers are clinically and biologically different. Tumor sidedness has significant prognostic and predictive value that will impact on the clinical management of metastatic colorectal cancer patients. Clinical research and medical care are closely related activities and the development of an integrated learning health care system will contribute to generating and applying clinically relevant medical knowledge producing benefits for present and future patients.

 

Learning objectives


• analyse colorectal cancer biology and molecular biomarkers of clinical relevance
• review biomarker-driven therapeutic strategies in patients with metastatic colorectal cancer
• evaluate the essentials of continuum of care approach for patients with metastatic colorectal
cancer within a multidisciplinary team setting
 

Scientific programme

Session I Molecular pathology and biomarkers
 
Chairs: H. Jaafar (UAE), S. Temraz (Lebanon), F. Vafaie Zadeh (Iran)

14.15  L1:  Critical pathways in metastatic colorectal cancer (mCRC)
      A. Sobrero (Italy)
   
14.45  L2:  Molecular biomarkers for mCRC
    A. Sobrero (Italy)
   
15.15    Coffee break

15.30  L3:  Evidence-based recommendations for molecular testing of mCRC
    C.H. Köhne (Germany)
   
16.00    ROUNDTABLE: Key guidelines questions
    J. Taieb (France), A. Sobrero (Italy), C.H. Köhne (Germany)
   
16.30  L4:  Tumor heterogeneity and blood-based biomarkers
    J. Taieb (France)
   
17.00    Closing remarks

17.15    End of the first day

Session II Treatment decisions in metastatic colorectal cancer (I)
 
Chairs: H. Jaafar (UAE), S. Temraz (Lebanon), F. Vafaie Zadeh (Iran)

09.00   L5:  RAS Wild-type and BRAF Wild-type mCRC
    A. Sobrero (Italy)
   
09.30   L6:  Primary tumor location of RAS wild-type mCRC: left vs right
    C.H. Köhne (Germany)
   
10.00     WORKING GROUPS: Clinical cases discussion
    J. Taieb (France), A. Sobrero (Italy), C.H. Köhne (Germany)

10.30     Coffee break

10.45   L7:  RAS mutated and BRAF mutated mCRC
    J. Taieb (France)
   
11.15    ROUNDTABLE: Frontline Strategies for Metastatic Colorectal Cancer
    J. Taieb (France), A. Sobrero (Italy), C.H. Köhne (Germany)
   
12.15     WORKING GROUPS: Clinical cases discussion
    J. Taieb (France), A. Sobrero (Italy), C.H. Köhne (Germany)

13.00    Lunch

Session III Treatment decisions in metastatic colorectal cancer (II)

Chairs: H. Jaafar (UAE), S. Temraz (Lebanon), F. Vafaie Zadeh (Iran)

14.00   L8:  Oligometastatic disease
    C.H. Köhne (Germany)
   
14.30  L9:  Therapy after progression
    J. Taieb (France)
   
15.00     WORKING GROUPS: Clinical cases discussion

    J. Taieb (France), A. Sobrero (Italy), C.H. Köhne (Germany)

15.30  L10:  Spotlight - Molecular classification of CRC
    C.H. Köhne (Germany)
   
15.45  L11:  Spotlight - Immunotherapy for mCRC
    J. Taieb (France)
   
16.00     Concluding remarks
    End of the workshop

Speakers

Julien Taieb

Head
Department of Gastroenterology and Digestive Oncology
Paris Descartes University
Hopital Européen Georges-Pompidou
20, Rue Leblanc
Paris, 75015, France
Slide kit
Claus-Henning Köhne
Oncology
Slide kit
Claus-Henning Köhne
Oncology
Slide kit
Claus-Henning Köhne
Oncology
Slide kit
Claus-Henning Köhne
Oncology
Slide kit
Alberto Sobrero
Oncology
Slide kit
Alberto Sobrero
Oncology
Slide kit
Julien Taieb
Oncology
Slide kit
Julien Taieb
Oncology
Slide kit
Julien Taieb
Oncology
Slide kit
Julien Taieb
Oncology